CardioTech gets FDA OK for wound dressing:
This article was originally published in Clinica
Executive Summary
The US FDA has given CardioTech International the green light to sell its new line of wound dressings designed to treat exuding and bleeding wounds. Representing an advanced wound dressing, AlgiMed absorbs wound exude almost instantaneously, and helps control minor bleeding, said the Woburn, Massachusetts firm. Made of calcium alginate, the dressing releases calcium - a potent pro-coagulant - on contact with blood, thus stopping bleeding. CardioTech expects to start selling the product in January 2004. It estimated the advanced wound care market at $1.5bn.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.